Leerink analyst Daniel Clark initiated coverage of Zoetis (ZTS) with an Outperform rating and $215 price target The firm notes . Zoetis has been one of the best performing names in animal health from a growth perspective, with a core competency of identifying new market opportunities and successfully executing against them. This has led to the company growing its top line and EPS at a rate above the broader space. Looking ahead, Leerink forecasts more above industry growth for Zoetis, with its assumptions supported by findings of a proprietary MEDACorp survey of 53 veterinarians.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ZTS:
- Zoetis Announces Major Leadership Changes for Growth
- Zoetis appoints Jamie Brannan chief commercial officer
- Zoetis Reports Strong Q3 2024 Financial Results
- Morning Movers: Air Transport Services jumps following $3.1B take-private deal
- Zoetis reports Q3 adjusted EPS $1.58, consensus $1.45
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
